Ischaemic heart disease was the principal cause of death in Malaysia in 2016, and ST-segment elevation myocardial infarction (STEMI) is noted as the deadliest clinical presentation of Acute Coronary Syndrome. At the National Heart Association of Malaysia’s 2018 Annual Scientific Meeting, Professor Dr Wan Azman Wan Ahmad shared his insights into the management of STEMI in Malaysia, highlighting the implications of the recent TREAT trial.
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
In this issue of MIMS Cardiology Supplement, we bring you clinical updates related to combating hypercholesterolaemia, highlighting the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering low-density lipoprotein-cholesterol levels.
At a cardiology conference held in Hilton Kuala Lumpur, senior consultant cardiologist Dato’ Sri Dr Azhari Rosman spoke on the importance of non–high-density lipoprotein cholesterol (non–HDL-C) and combination therapy as a novel approach in the management of atherogenic dyslipidemia (AD).
Through a cardiology webcast hosted by Pfizer, Dr Jeyamalar Rajadurai, Dr Salim Virani and Dr Pamela Morris shared their insights into the importance of primary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
Coronary artery disease is prevalent among patients who have undergone coronary angiography, according to a new Philippine study presented at the recently concluded 2019 Congress of the Asian Pacific Society of Cardiology (APSC 2019). However, the obtained rates remain lower than that in other Asian countries.
About one of 10 patients with myocardial infarction (MI) at a young age present with clinically defined familial hypercholesterolaemia (FH), reports a study. Furthermore, only two-thirds of FH patients have been discharged on high-intensity statin therapy, and several present with elevated low-density lipoprotein cholesterol (LDL-C) at 1 year.